|
Market Cap (24-Jun) $27,342,400 (1,032nd) |
Close (30-Jun) $0.008 |
Volume (30-Jun) 285,280 |
Shortsold (12-Dec) 6,497 (0.00%) (681st) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS -0.09 |
EX1 released this announcement to the ASX on 13 October 2022, 16:54. The announcement is not marked as price sensitive, and is 14 page(s) in length and 3MB in size.
You can view all announcements from EX1 and see how they appear on a price chart on the announcements page.
At the date of this announcement, EX1 was 0.012% short sold according to ASIC data. It was ranked the 613th most shorted stock on the ASX. It remains ranked 681st as of the latest reported data (12 December 2022).
| Other Recent Announcements from EX1 | |
|---|---|
| Initial Director's Interest Notice - MD | 22 June 2023, 11:52 |
| Change of Director's Interest Notice - CB | 22 June 2023, 11:51 |
| Final Director's Interest Notice - JW | 22 June 2023, 11:50 |
| Upcoming Webinar | 13 October 2022, 16:54 |
| EX1 Building Momentum with in-house Products | 12 October 2022, 8:16 |
| Investor Presentation | 7 October 2022, 8:17 |
| Study results indicate exosomes safe for clinical pursuit | 28 September 2022, 8:14 |
You must be logged in to post a reply.
Exopharm 